ARGNF / argenx SE - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

Exhibit 99.1 argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026 · ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety · RHO+ data in Sjogren’s disease indicate maintenance of response following switch to biweekly dosing · Cross-indication analysis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2026 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

Exhibit 99.1 argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG · VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative · Patients treated with VYVGART in the ADAPT SER

Leading a new era of innovation in immunology 1 Q 2 0 2 6 F I N A N C I A L R E S U L T S C A L L M A Y 7 , 2 0 2 6 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes onl

argxq1slides Leading a new era of innovation in immunology 1 Q 2 0 2 6 F I N A N C I A L R E S U L T S C A L L M A Y 7 , 2 0 2 6 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

argenx Reports First Quarter 2026 Financial Results and Provides Business Update $1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR antibody negative (“seronegative”) gMG PDUFA is May 10, 2026 Man

argenx Reports First Quarter 2026 Financial Results and Provides Business Update $1.

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer Leadership transition marks next evolution of growth

Exhibit 99.1 argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today anno

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

Exhibit 99.1 argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP · ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population · ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indicati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

argenx announces Annual General Meeting of Shareholders on May 6, 2026

Exhibit 99.1 argenx announces Annual General Meeting of Shareholders on May 6, 2026 March 20, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at th

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 1.In connection with the Annual Report on Form 20-F of argenx SE (the "Company") for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pur

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-292200, 333-225375, 333-274721 and 333-258253 on Form S-8 of our report dated March 20, 2025, relating to the financial statements of argenx SE appearing in this Annual Report on Form 20-F for the year ended December 31, 2025. /s/ Deloitte Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Karl Gubitz, certify that: 1.I have reviewed this Annual Report on Form 20-F of argenx SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fac

EQUITY INCENTIVE PLAN 2026 as approved by the board of directors of argenx SE on 4 March 2026

Exhibit 4.3 EQUITY INCENTIVE PLAN 2026 as approved by the board of directors of argenx SE on 4 March 2026 1.INTRODUCTION 1.1.Purpose Our success in generating long-term value creation for our stakeholders depends on our ability to discover and develop innovative medicines that address unmet medical needs, and our ability to successfully bring those medicines to patients and ultimately generate fin

Table of Contents

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

RULES (BY-LAWS) FOR THE BOARD OF DIRECTORS OF ARGENX SE as approved by the Board of argenx SE on 22 July 2025

Exhibit 1.2 RULES (BY-LAWS) FOR THE BOARD OF DIRECTORS OF ARGENX SE as approved by the Board of argenx SE on 22 July 2025 1.Status of these Rules These rules (the "Rules") of the board of directors (the “Board”) of argenx SE (the “Company”) have been established by the Board on 22 July 2025 replacing any previously applicable Board Rules. 2.Board Composition and Committees 2.1.Executive and non-ex

DESCRIPTION OF SHARE CAPITAL

Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL argenx SE (Company, argenx, we, us, and our) has one class of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act): ordinary shares, including ordinary shares represented by American Depositary Shares (ADSs, each an ADS). The following description is a summary of certain information relating to ou

Disclaimer PDF print – this document is only a “printed version” and is not the original annual financial reporting including the audited financial statements pursuant to Article 361 of Book 2 of the Dutch Civil Code. These original annual financial

argenx2025integratedannu Disclaimer PDF print – this document is only a “printed version” and is not the original annual financial reporting including the audited financial statements pursuant to Article 361 of Book 2 of the Dutch Civil Code.

CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Tim Van Hauwermeiren, certify that: 1.I have reviewed this Annual Report on Form 20-F of argenx SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To: the shareholders and the board of directors of argenx SE We consent to the incorporation by reference in the Registration Statement (Form S-8 Nos. 333-225375, 333-258253, 333-274721 and 333-292200) pertaining to the Equity Incentive Plan of argenx SE of our report dated March 19, 2026, with respect to the consolidated financ

REMUNERATION POLICY 2025 subject to approval at the Extraordinary General Meeting of 18 November 2025

Exhibit 4.5 REMUNERATION POLICY 2025 subject to approval at the Extraordinary General Meeting of 18 November 2025 1. Background Under Dutch law, remuneration policies are subject to a binding vote at the annual general meeting of shareholders at least every four years. As our current remuneration policy was approved in 2021, we are submitting this revised policy (the “Policy”) for approval at our

ARGENX SE INSIDER TRADING POLICY

Exhibit 11.1 ARGENX SE INSIDER TRADING POLICY 1 Exhibit 11.1 Table of contents 1.Introduction 3 2.Summary 4 3.Rules for all Employees and their PCAs 5 4.Additional Rules for PDMRs and Designated Persons and their PCAs 9 5.Additional obligations of PDMRs and their PCAs 11 6.Additional Rules for Board Members 12 7.Definitions 13 Schedule 1 Notifiable transactions BY PDMRs 18 2 Exhibit 11.1 1.Introduct

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of argenx SE (the "Company") for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Exhibit 99.1 argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline · Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG · Additional data from ADAPT SERON – the largest study of patients with gMG who do not have det

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

Exhibit 99.1 argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis · Study met primary endpoint (p-value = 0.012) · First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG · Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administ

Leading a new era of innovation in immunology 1 4 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L F E B R U A R Y 2 6 , 2 0 2 6 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informationa

argxq4slidesfinal Leading a new era of innovation in immunology 1 4 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L F E B R U A R Y 2 6 , 2 0 2 6 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose.

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update $1.3 billion in fourth-quarter and $4.2 billion in full-year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operat

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update $1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

ARGENX SE UNAUDITED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As of December 31, (in thousands of $) 2025 2024 2023 Assets Non‑current assets Property, plant and equipment $ 48,247 $ 43,517 $ 22,675 Intangible assets 272,103 181,445 125,228 Defer

ARGENX SE UNAUDITED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As of December 31, (in thousands of $) 2025 2024 2023 Assets Non‑current assets Property, plant and equipment $ 48,247 $ 43,517 $ 22,675 Intangible assets 272,103 181,445 125,228 Deferred tax assets 1,295,853 924,299 97,211 Research and development incentive receivables 86,212 94,854 76,706 Investment in a joint venture 3,378 9,268

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

Exhibit 99.1 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendat

Exhibit 99.2 Leading a new era of innovation in immunology 1 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee,

argenx Highlights 2026 Strategic Priorities Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 pat

Exhibit 99.1 argenx Highlights 2026 Strategic Priorities Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

argenx Announces Leadership Transition Marking Next Evolution of Growth Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director

Exhibit 99.1 argenx Announces Leadership Transition Marking Next Evolution of Growth Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to imp

As filed with the U.S. Securities and Exchange Commission on December 17, 2025

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARGENX SE (Exact name of registrant as specified in its charter) The Netherlands Not applicable (State or other jurisdiction of incorporation or organization) (I.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 ARGENX SE Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary shares, nominal value of EUR0.

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

Exhibit 99.1 argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

argenx Announces Results of Extraordinary General Meeting of Shareholders

Exhibit 99.1 argenx Announces Results of Extraordinary General Meeting of Shareholders November 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

Reaching Patients Through Immunology Innovation 3 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L O C T O B E R 3 0 , 2 0 2 5 1 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informationa

argxq3investorpresentati Reaching Patients Through Immunology Innovation 3 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L O C T O B E R 3 0 , 2 0 2 5 1 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose.

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update $1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update $1.

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

Exhibit 99.1 argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients · VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activity · Final ADAPT SC+ results show ~60% of VYVGART gMG patients achieved minimal sympto

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session

Exhibit 99.1 argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session · Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patients · Real-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomes · More than 40 abstracts across

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

Exhibit 99.1 argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-380

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive off

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Exhibit 99.1 argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - Study met primary endpoint (p-value=0.0068) - First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative - Supplemental Biologics License Application (sBLA) to be subm

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to a

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands. (Address of principal executive offi

Reaching Patients Through Immunology Innovation 2 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L J U L Y 3 1 , 2 0 2 5 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purpos

argenx2q2025investorpres Reaching Patients Through Immunology Innovation 2 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L J U L Y 3 1 , 2 0 2 5 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose.

argenx Half-Year 2025 Financial Report

2025 Half-Year Financial Report argenx Half-Year 2025 Financial Report 1 Table of Contents Management report 2 1Main events in the first six months of 2025 2 2Financial highlights 4 3Risk factors 5 4Forward-looking statements 5 5Statement of the board of directors 6 Unaudited condensed consolidated interim financial statements 7 Unaudited condensed consolidated interim statements of financial posi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates stro

Exhibit 99.1 argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Exhibit 99.1 argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy · VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP · Approval based on ADHERE clinical trial, the largest study of CIDP patients to date · First nove

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease

Exhibit 99.1 argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease · ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod · RHO data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcome

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

argenx Announces Results of Annual General Meeting of Shareholders

Exhibit 99.1 argenx Announces Results of Annual General Meeting of Shareholders May 28, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025. 91.1% of the Company’s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

argenx Reports First Quarter 2025 Financial Results and Provides Business Update $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global ex

argenx Reports First Quarter 2025 Financial Results and Provides Business Update $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update.

Reaching Patients Through Immunology Innovation 1 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L M A Y 8 , 2 0 2 5 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes o

Reaching Patients Through Immunology Innovation 1 Q 2 0 2 5 F I N A N C I A L R E S U L T S C A L L M A Y 8 , 2 0 2 5 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-3809

6-K 1 tm2513185d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Ad

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

EX-99.1 2 tm2513185d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP · First novel mechanism of action for CIDP treatment in more than 30 years · CHMP positive opinion based on ADHERE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Exhibit 99.1 argenx Announces Annual General Meeting of Shareholders on May 27, 2025 April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Exhibit 99.1 argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy · VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe · Self-injection provides gMG and CIDP patients with flexibility for when and w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Exhibit 99.1 argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP · ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients · ADHERE+ oral presentation features long-term CIDP data demonstrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

DESCRIPTION OF SHARE CAPITAL

Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL argenx SE (Company, argenx, we, us, and our) has one class of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act): ordinary shares, including ordinary shares represented by American Depositary Shares (ADSs, each an ADS). The following description is a summary of certain information relating to ou

Table of Contents

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Karl Gubitz, certify that: 1.I have reviewed this Annual Report on Form 20-F of argenx SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fac

Annual Report 2024 2024 Annual Report including the Annual Financial Statements for the year ended December 31, 2024 This Annual Report is filed with the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten, AFM). The fo

Annual Report 2024 2024 Annual Report including the Annual Financial Statements for the year ended December 31, 2024 This Annual Report is filed with the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten, AFM).

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 1.In connection with the Annual Report on Form 20-F of argenx SE (the "Company") for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pur

CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Tim Van Hauwermeiren, certify that: 1.I have reviewed this Annual Report on Form 20-F of argenx SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat

Consent of independent registered public accounting firm

Exhibit 15.1 Consent of independent registered public accounting firm We consent to the incorporation by reference in Registration Statements Nos. 333-225375, 333-258253 and 333-274721 on Form S-8 of our reports dated March 20, 2025, relating to the financial statements of argenx SE and the effectiveness of argenx SE’s internal control over financial reporting appearing in this Annual Report on Fo

EQUITY INCENTIVE PLAN 2024 as approved by the board of directors of argenx SE on 27 February 2024

Exhibit 4.3 EQUITY INCENTIVE PLAN 2024 as approved by the board of directors of argenx SE on 27 February 2024 1.INTRODUCTION 1.1.Purpose Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology. Our future success is largely dependent on our ability to attract and retain highly qualified individuals such as you

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

Deloitte Accountants B.V.

Exhibit 15.2 Deloitte Accountants B.V. Audit & Assurance None Wilhelminakade 1 3072 AP Rotterdam P.O. Box 2031 3000 CA Rotterdam The Netherlands Tel: +31 (0)88 288 2888 www.deloitte.nl March 20, 2025 Securities and Exchange Commission 100 F Street, N.E. WASHINGTON, D.C. 20549-7561 Dear Sirs/Madams, We have read Item 16F of argenx SE's Form 20-F dated March 20, 2025, and we agree with the statement

Part AExecutive Director and Non-Executive Director

Exhibit 11.1 Insider Trading Policy Page 1 of 21 1.PURPOSE The Insider Trading Policy is intended to raise and maintain Insiders’ awareness about the prohibition of trading in the Company’s Financial Instruments while having Inside Information and about the other related prohibitions under the DFSA, the BFSA, the Market Abuse Regulation and the US federal securities laws and to ensure that any Ins

Unofficial translation of the articles of association of

Exhibit 1.1 Unofficial translation of the articles of association of argenx SE as they read after the execution of a deed of partial amendment of the articles of association before Dirk-Jan Jeroen Smit, civil law notary in Amsterdam, the Netherlands, on 7 May 2024. Please note that this is an unofficial office translation, in which an attempt has been made to be as literal as possible without jeop

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of argenx SE (the "Company") for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursu

RULES (BY-LAWS) FOR THE BOARD OF DIRECTORS OF ARGENX SE as approved by the board of directors of argenx SE on 12 December 2023

Exhibit 1.2 RULES (BY-LAWS) FOR THE BOARD OF DIRECTORS OF ARGENX SE as approved by the board of directors of argenx SE on 12 December 2023 1.Status of these Rules These rules (the "Rules") of the board of directors (the “Board”) of argenx SE (the “Company”) have been established by the Board on 12 December 2023 replacing any previously applicable Board Rules. 2.Board Composition and Committees 2.1

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

Exhibit 99.1 argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting · Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART Hytrulo · gMG patients on VYVGART achieve rapid, substantial, and sustained efficacy across multiple dosing regimens, supp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

ARGENX SE UNAUDITED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As of December 31, (in thousands of $) 2024 2023 2022 Assets Non‑current assets Property, plant and equipment $ 43,517 $ 22,675 $ 16,234 Intangible assets 181,445 125,228 174,901 Defer

ARGENX SE UNAUDITED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As of December 31, (in thousands of $) 2024 2023 2022 Assets Non‑current assets Property, plant and equipment $ 43,517 $ 22,675 $ 16,234 Intangible assets 181,445 125,228 174,901 Deferred tax assets 924,299 97,211 79,222 Research and development incentive receivables 94,854 76,706 47,488 Investment in a joint venture 9,268 9,912 1,3

Reaching Patients Through Immunology Innovation 4 Q 2 0 2 4 F I N A N C I A L R E S U L T S C A L L F E B R U A R Y 2 7 , 2 0 2 5 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informationa

Reaching Patients Through Immunology Innovation 4 Q 2 0 2 4 F I N A N C I A L R E S U L T S C A L L F E B R U A R Y 2 7 , 2 0 2 5 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose.

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update $737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update $737 million in fourth quarter and $2.

EX-99

EX-99 2 exhibit99.txt Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management

Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendat

Exhibit 99.2 The Next Wave of Innovation 43rd ANNUAL JP MORGAN HEALTHCARE CONFERENCE JANUARY 13, 2025 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

argenx Highlights 2025 Strategic Priorities Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching pati

Exhibit 99.1 argenx Highlights 2025 Strategic Priorities Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm 10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of in

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravi

Exhibit 99.1 argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - Phase 2 data establish proof-of-concept of efgartigimod SC in myositis - Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) unde

Exhibit 99.1 argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - Phase 2 data establish proof-of-concept of efgartigimod SC in myositis - Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA - Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment op

ARGX / argenx SE - Depositary Receipt (Common Stock) / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 argx13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) ARGENX SE - ADR (Name of Issuer) ADR (Title of Class of Securities) 04016X101 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to whi

BE:ARGX / argenx SE / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.10 ARGENX SE COMMON STOCK Cusip #N0610Q109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #N0610Q109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,792,909 Item 6: 0 Item 7: 5,074,684 Item 8: 0 Item 9: 5,074,68

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China

Exhibit 99.1 argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) toda

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update $573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Manage

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update $573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated information - Inside information October 31, 2024 7:00AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2024 financial results and provided a business update.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogteweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

Reaching Patients Through Immunology Innovation 3 Q 2 0 2 4 E A R N I N G S C A L L | O c t o b e r 3 1 , 2 0 2 4 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only

Reaching Patients Through Immunology Innovation 3 Q 2 0 2 4 E A R N I N G S C A L L | O c t o b e r 3 1 , 2 0 2 4 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose.

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions Long-term and

Exhibit 99.1 argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa

Exhibit 99.1 argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ARGENX SE UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

Table of Contents TABLE OF CONTENTS MANAGEMENT REPORT 1. MAIN EVENTS IN THE SIX MONTHS OF 2024 2 2. FINANCIAL HIGHLIGHTS 3 3. RISK FACTORS 4 4. FORWARD-LOOKING STATEMENTS 4 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION 6 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS 8 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LO

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update $478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin f

Ex* reflects cash, cash equivalents and current financial assets hibit 99.1 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update $478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational studies across efgartigimod and empasiprubar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical be

Exhibit 99.1 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse fo

Exhibit 99.1 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) F

Exhibit 99.1 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART® and VYVGART

VYVGART® HYTRULO NOW INDICATED FOR CIDP FDA APPROVAL CALL | JUNE 21, 2024 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing c

Exhibit 99.2 VYVGART® HYTRULO NOW INDICATED FOR CIDP FDA APPROVAL CALL | JUNE 21, 2024 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024 R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropat

Exhibit 99.1 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024 R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlight

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

argenx Reports First Quarter 2024 Financial Results and Provides Business Update $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-

Exhibit 99.1 argenx Reports First Quarter 2024 Financial Results and Provides Business Update $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

argenx announces results of Annual General Meeting of Shareholders

Exhibit 99.1 argenx announces results of Annual General Meeting of Shareholders May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real

Exhibit 99.1 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment Apri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

PROXY FORM ANNUAL GENERAL MEETING ARGENX SE MAY 7, 2024

Exhibit 99.5 PROXY FORM ANNUAL GENERAL MEETING ARGENX SE MAY 7, 2024 IMPORTANT NOTICE: for the annual general meeting 2024 argenx uses the e-voting system of ABN AMRO. The company therefore kindly requests all shareholders who wish to vote at the general meeting but cannot/do not wish to attend, to use the proxy/e-voting services of ABN via HTTPS://WWW.ABNAMRO.SECURITIESVOTING.COM/SHAREHOLDER/ The

ANNUAL GENERAL MEETING OF ARGENX SE OF 7 MAY 2024

Exhibit 99.3 ANNUAL GENERAL MEETING OF ARGENX SE OF 7 MAY 2024 AGENDA 1. Opening 2. Report on the 2023 financial year (discussion item) 3. The 2023 remuneration report (advisory non-binding voting item) 4. Discussion and adoption of the 2023 annual report and annual accounts: a. Discussion of the 2023 annual report (discussion item) b. Adoption of the 2023 annual accounts (voting item) c. Corporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

ANNUAL GENERAL MEETING 7 MAY 2024 OF ARGENX SE EXPLANATORY NOTES

Exhibit 99.4 ANNUAL GENERAL MEETING 7 MAY 2024 OF ARGENX SE EXPLANATORY NOTES The following items on the agenda of the meeting of argenx SE (the "Company") shall be discussed and/or put to a vote. The numbers in the list correspond to the numbers on the agenda. 2. Report on the 2023 financial year (discussion item) This agenda item includes an account of the financial year 2023. 3. The 2023 remune

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures

Exhibit 99.1 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to impr

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

Exhibit 99.1 argenx Announces Annual General Meeting of Shareholders on May 7, 2024 March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 7, 2024 at the

CONVOCATION ANNUAL GENERAL MEETING OF ARGENX SE 7 MAY 2024

Exhibit 99.2 CONVOCATION ANNUAL GENERAL MEETING OF ARGENX SE 7 MAY 2024 argenx SE (the "Company") hereby invites its shareholders and all other persons with meeting rights to attend its annual general meeting of shareholders ("AGM") to be held at 13:00 CET on Tuesday, May 7, 2024 at Hilton Hotel Schiphol, Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. We would like to emphasize and enc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in J

Exhibit 99.1 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March 26, 2024 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Na

Disclaimer PDF print – this document is only a “printed version” and is not the original annual financial reporting including the audited financial statements pursuant to Article 361 of Book 2 of the Dutch Civil Code. These original annual financial

Exhibit 99.1 AnnualReport2023 Disclaimer PDF print – this document is only a “printed version” and is not the original annual financial reporting including the audited financial statements pursuant to Article 361 of Book 2 of the Dutch Civil Code. These original annual financial reporting included in the audited financial statements and the auditor’s report thereto, are included in the single repo

CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Karl Gubitz, certify that: 1.I have reviewed this Annual Report on Form 20-F of argenx SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fac

EQUITY INCENTIVE PLAN 2023 as approved by the board of directors of argenx SE on 2 May 2023

Exhibit 4.4 EQUITY INCENTIVE PLAN 2023 as approved by the board of directors of argenx SE on 2 May 2023 1.INTRODUCTION 2.GRANTING EQUITY INCENTIVES 1.1.PURPOSE 2.1.ELIGIBILITY TO PARTICIPATE IN THIS PLAN Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology. Our future success is largely dependent on our abi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

argenx SE EXECUTIVE COMPENSATION CLAWBACK POLICY

Exhibit 97.1 argenx SE EXECUTIVE COMPENSATION CLAWBACK POLICY 1.Purpose. The purpose of this Policy is to set forth the circumstances under which Executive Officers of the Company will be required to repay or return certain Excess Awarded Compensation to members of the Company Group. The Board has adopted this Policy in accordance with the Clawback Rule and the Listing Rule and it is intended to c

DESCRIPTION OF SHARE CAPITAL

Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL argenx SE (Company, argenx, we, us, and our) has one class of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act): ordinary shares, including ordinary shares represented by American Depositary Shares (ADSs). The following description is a summary of certain information relating to our share capit

Consent of independent registered public accounting firm

Exhibit 15.1 Consent of independent registered public accounting firm We consent to the incorporation by reference in Registration Statements Nos. 333-225375, 333-258253 and 333-274721 on Form S-8 and Registration Statement No. 333-258251 on Form F-3 of our reports dated March 21, 2024, relating to the financial statements of argenx SE and the effectiveness of argenx SE’s internal control over fin

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of argenx SE (the "Company") for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursu

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of argenx SE (the "Company") for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Tim Van Hauwermeiren, certify that: 1.I have reviewed this Annual Report on Form 20-F of argenx SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-

Exhibit 99.1 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART® and VYVGART® Hytrulo in gMG patients Mar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

ARGENX SE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Exhibit 99.3 ARGENX SE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As of December 31, (in thousands of $) 2023 2022 2021 ASSETS Non-current assets Property, plant and equipment $ 22,675 $ 16,234 $ 15,844 Intangible assets 125,228 174,901 171,684 Deferred tax asset 97,211 79,222 32,191 Research and development incentive receivables 76,706 47,488 32,707 Investment in joint venture 9,912 1,323 — Pr

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update $374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA w

Exhibit 99.1 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update $374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024 Management

Reaching Patients through Immunology Innovation F Y / 4 Q 2 0 2 3 E A R N I N G S C A L L | F E B R U A R Y 2 9 , 2 0 2 4 Forward Looking Statements • This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purp

Exhibit 99.2 Reaching Patients through Immunology Innovation F Y / 4 Q 2 0 2 3 E A R N I N G S C A L L | F E B R U A R Y 2 9 , 2 0 2 4 Forward Looking Statements • This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If

Exhibit 99.1 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM CET Amsterdam,

ARGX / argenx SE - Depositary Receipt (Common Stock) / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 argx13gadec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7) ARGENX SE - ADR (Name of Issuer) ADR (Title of Class of Securities) 04016X101 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to whic

ARGX / argenx SE - Depositary Receipt (Common Stock) / Artisan Partners Limited Partnership - SC 13G Passive Investment

SC 13G 1 d758086dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No.  )* Argenx SE (Name of Issuer) American Depositary Shares (Title of Class of Securit

JOINT FILING AGREEMENT

EX-99.1 2 d758086dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTIS

ARGNF / argenx SE / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.9 ARGENX SE COMMON STOCK Cusip #N0610Q109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #N0610Q109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,017,222 Item 6: 0 Item 7: 4,173,842 Item 8: 0 Item 9: 4,173,842

ARGX / argenx SE - Depositary Receipt (Common Stock) / BlackRock Inc. Passive Investment

nl0010832176020124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) ARGENX SE - (Name of Issuer) Common Stock - (Title of Class of Securities) BWNH4H6 - (SEDOL Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Exhibit 99.1 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis • Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

Forward Looking Statements This presentation has been prepared by argenx SE (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendat

Exhibit 99.2 argenx The Next Chapter JP MORGAN HEALTHCARE CONFERENCE JANUARY 8, 2024 1 Forward Looking Statements This presentation has been prepared by argenx SE (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company

argenx Highlights 2024 Strategic Priorities Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Re

Exhibit 99.1 argenx Highlights 2024 Strategic Priorities Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN Data from six Phase 2 proof-of-concep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus ●    ADDRESS study did not meet primary or secondary endpoints ●    Pemphigus deprioritized as efgartigimod indication ●    Update on BALLAD study GO/NO GO decision ●  

Exhibit 99.1 argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus ●    ADDRESS study did not meet primary or secondary endpoints ●    Pemphigus deprioritized as efgartigimod indication ●    Update on BALLAD study GO/NO GO decision ●    Conference call scheduled for today, December 20, 2023, at 8:30am ET (2:30pm CET) Regulated Information – Inside Information December 2

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia -            Study did not meet primary or secondary endpoints -            Favorable safety and tolerability profile consistent with previous

Exhibit 99.1 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia -            Study did not meet primary or secondary endpoints -            Favorable safety and tolerability profile consistent with previous clinical trials -            Conference call scheduled for today, November 28, 2023 at 8:30am ET (2:30pm CET) Regulated information – Ins

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed

Exhibit 99.1 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to enable broad access to VYVGART SC for eligible patients Amsterdam,

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, in

Exhibit 99.1 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized myasthenia gravis (gMG) Patients treated with VYVGART experienced consistent impr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive o

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update - $329 million in third quarter global net product sales - On track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 - Results from the ADVANCE-IV study publish

Exhibit 99.1 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update - $329 million in third quarter global net product sales - On track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 - Results from the ADVANCE-IV study published in The Lancet - Management to host conference call today at 1:30 pm CET (8:30 am ET) October 31, 2023 Amsterdam, the Netherlands – arg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of

Driving Sustained Growth Across the Business Consistent Execution + Perpetual Innovation Reaching More Patients Geographic Expansion Pioneer FcRn Class of Medicines Broaden Immunology Pipeline Double-digit growth quarter over quarter Approval in Cana

Exhibit 99.2 Third Quarter 2023 Financial Results and Business Update October 31, 2023 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company

As filed with the U.S. Securities and Exchange Commission on September 27, 2023

As filed with the U.S. Securities and Exchange Commission on September 27, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARGENX SE (Exact name of registrant as specified in its charter) The Netherlands Not applicable (State or other jurisdiction of incorporation or organization) (I

Calculation of Filing Fee Tables Form S-8 (Form Type) ARGENX SE (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ARGENX SE (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (3) Equity Ordinary shares, nominal value of €0.

EQUITY INCENTIVE PLAN 2023 as approved by the board of directors of argenx SE on 2 May 2023

Exhibit 99.2 EQUITY INCENTIVE PLAN 2023 as approved by the board of directors of argenx SE on 2 May 2023 1. INTRODUCTION 1.1. PURPOSE Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology. Our future success is largely dependent on our ability to attract and retain highly qualified individuals such as you, a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis ●  VYVGART ® is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada ●  Approval based on the positive

Exhibit 99.1 argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis ●  VYVGART ® is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada ●  Approval based on the positive Phase 3 ADAPT trial (p<0.001) showing 68% of VYVGART-treated patients were responders on the MG-ADL scale compared to 30% of placebo pat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ARGENX SE UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

Table of Contents TABLE OF CONTENTS UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION 2 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS 4 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME AND LOSS 5 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS 6 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGE

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update - $269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales - VYVGART® Hytrulo now available in the U.S. with first vials ship

Exhibit 99.1 argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update - $269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales - VYVGART® Hytrulo now available in the U.S. with first vials shipped in July - Global VYVGART expansion continued with commercial launch in Italy and distribution agreement with Handok in South Korea -

argenx raises $1.1 billion in gross proceeds in a global offering

Exhibit 99.2 Regulated information — Inside information argenx raises $1.1 billion in gross proceeds in a global offering July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today the pricing of a global offer

argenx announces launch of proposed global offering

Exhibit 99.1 Regulated information — Inside information argenx announces launch of proposed global offering July 17, 2023 Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today that it has commenced a global offering of $750 million (approximately €668.6 mill

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

ARGENX SE 2,244,899 Ordinary Shares (including 1,580,981 American Depositary Shares, each Representing One Ordinary Share) UNDERWRITING AGREEMENT

Exhibit 1.1 ARGENX SE 2,244,899 Ordinary Shares (including 1,580,981 American Depositary Shares, each Representing One Ordinary Share) UNDERWRITING AGREEMENT July 18, 2023 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC BofA Securities, Inc. Cowen and Company, LLC as Representatives of the several Underwriters named in Schedule A hereto c/o J.P. Morgan Securities LLC 38

Active bookrunners

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-258251   Prospectus supplement (To prospectus dated July 29, 2021) 2,244,899 Ordinary shares (Including ordinary shares represented by American depositary shares) We are offering 2,244,899 ordinary shares (including ordinary shares represented by American Depositary Shares, or ADSs), in a global offering. We are offering ord

Calculation of Filing Fee Tables (Form Type) ARGENX SE (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) ARGENX SE (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary Shares, nominal value of €0.

argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy - Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25

Exhibit 99.1 argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy - Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo - IgG autoantibodies shown to play significant role in underlying CIDP disease biology - Favora

Active bookrunners

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

ADHERE Study T opline Results July 17 , 2023

Exhibit 99.2 ADHERE Study T opline Results July 17 , 2023 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, ag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Exhibit 99.1 argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China ● First-and-only approved FcRn antagonist for gMG patients by NMPA ● 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients trea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offic

Regulated Information/Inside Information

Exhibit 99.2 argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis • VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) • With this approval, argenx broadens innovative gMG product offering and demonstrates cont

Regulated Information/Inside Information

Exhibit 99.1 argenx initiates second cohort of Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy · Independent Data Monitoring Committee recommended study continuation based on the favorable safety profile observed in the first dose cohort · Early efficacy signals support proof-of-concept of empasiprubart in multifocal motor neuropathy Regulated Information/Inside Information Amst

VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive NOW TWO FDA-APPROVED PRODUCTS

Exhibit 99.3 VYVGART ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) FDA Approval Call June 21, 2023 2 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the pres

First Quarter 2023 Financial Results and Business Update May 4, 2023 Continued Progress Across Business Reaching More gMG Patients Broaden Immunology Pipeline Geographic Expansion $218M in global product revenues in first quarter 2023 5 Global VYVGAR

Exhibit 99.2 First Quarter 2023 Financial Results and Business Update May 4, 2023 2 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38097

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive office

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38097

6-K 1 tm2314617d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Addr

Annual general meeting of argenx SE May 2, 2023 – Voting results

Exhibit 99.2 Annual general meeting of argenx SE May 2, 2023 – Voting results Total number of outstanding shares at the record date. 55,685,883 Total shares present or represented at the AGM. 46,781,165 Percentage represented share capital at AGM. 84.01 % Total valid votes at AGM. 46,781,165 Agenda Item Resolution 3 Advisory vote on the 2022 remuneration report. Votes for 20,460,533 (44.14%) Votes

argenx Reports First Quarter 2023 Financial Results and Provides Business Update - $218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales - VYVGART received marketing authorization in Israel through partnership with

Exhibit 99.1 argenx Reports First Quarter 2023 Financial Results and Provides Business Update - $218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales - VYVGART received marketing authorization in Israel through partnership with Medison - 88 events achieved in ADHERE trial; topline data now expected in July 2023 - Enrollment completed in ADVANCE-SC and ADDRESS tri

argenx announces results of Annual General Meeting of Shareholders

Exhibit 99.1 argenx announces results of Annual General Meeting of Shareholders May 3, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its annual general meeting of shareholders held yesterday. All items on the agenda received a majority

argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting

Exhibit 99.1 argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting Amsterdam, the Netherlands – 04/18/2023 argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Exhibit 99.1 argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology • Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies • Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands – 04/17/2023 argenx SE (Euronext & Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-3809

6-K 1 tm2312788d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

Articles of Association (English translation), as amended

Exhibit 1.1 Unofficial translation of the articles of association of argenx SE as they read after the execution of a deed of partial amendment of the articles of association before Dirk-Jan Jeroen Smit, civil law notary in Amsterdam, the Netherlands, on 10 May 2022. Please note that this is an unofficial office translation, in which an attempt has been made to be as literal as possible without jeo

Argenx Equity Incentive Plan 2021

Exhibit 4.4 EQUITY INCENTIVE PLAN 2021 as approved by the board of directors of argenx SE on 15 December 2021 1.INTRODUCTION 2.GRANTING EQUITY INCENTIVES 1.1.PURPOSE 2.1.ELIGIBILITY TO PARTICIPATE IN THIS PLAN Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology. Our future success is largely dependent on o

Description of Share Capital

Exhibit 2.3 DESCRIPTION OF SHARE CAPITAL argenx SE (company, argenx, we, us, and our) has one class of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act): ordinary shares, including ordinary shares represented by American Depositary Shares (ADSs). The following description is a summary of certain information relating to our share capit

Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of argenx SE (the “Company”) for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Karl Gubitz, certify that: 1. I have reviewed this Annual Report on Form 20-F of argenx SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f

Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of argenx SE (the “Company”) for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursu

Remuneration Policy

Exhibit 4.9 REMUNERATION POLICY 2021 approved at our general meeting of 11 May 2021 1.INTRODUCTION AND KEY PRINCIPLES - attract, retain and motivate superior talent to serve on our senior leadership team by offering market competitive remuneration packages that are strategically aligned in the regions in which we operate; - promote long-term value creation over short-term success through co-owners

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Tim Van Hauwermeiren, certify that: 1. I have reviewed this Annual Report on Form 20-F of argenx SE; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m

Consent of Deloitte Accountants B.V.

Exhibit 15.1 Consent of independent registered public accounting firm We consent to the incorporation by reference in Registration Statements 333-258253 and 333-225375 on Form S-8 and Registration Statement No. 333-258251 on Form F-3 of our reports dated March 16, 2023, relating to the financial statements of argenx SE and the effectiveness of argenx SE’s internal control over financial reporting,

argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) wh

Exhibit 99.1 argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were resp

Rules for the Board of Directors

Exhibit 1.2 RULES (BY-LAWS) FOR THE BOARD OF DIRECTORS OF ARGENX SE as approved by the board of directors of argenx SE on 2 March 2021 1. STATUS OF THESE RULES These rules of the board of directors (the "Rules") have been established by the board of directors pursuant to article 10, paragraph 4 of the Articles of Association. These Rules are supplementary to the provisions concerning the board of

argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update $173 million in fourth quarter and $401 million in full year 2022 VYVGART® (efgartigimod alfa-fcab) global net product sales FDA review ongoing for SC efgarti

Exhibit 99.2 argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update $173 million in fourth quarter and $401 million in full year 2022 VYVGART® (efgartigimod alfa-fcab) global net product sales FDA review ongoing for SC efgartigimod BLA with PDUFA target action date of June 20, 2023; MAA filed in Japan with approval decision expected by first quarter of 2024 ADH

argenx Announces Planned Transition of Chief Operating Officer

Exhibit 99.1 argenx Announces Planned Transition of Chief Operating Officer · Karen Massey appointed as Chief Operating Officer, effective March 13, 2023 · Keith Woods to retire and serve as Advisor on argenx Board of Directors March 2, 2023 Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe au

Fourth Quarter and Full Year 2022 Financial Results and Business Update March 2, 2023

Exhibit 99.3 Fourth Quarter and Full Year 2022 Financial Results and Business Update March 2, 2023 2 Forward Looking Statements This presentation has been prepared by argenx se (“ argenx ” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-3809

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive offi

ARGX / argenx SE ADS / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) ARGENX SE - ADR (Name of Issuer) ADR (Title of Class of Securities) 04016X101 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x]

ARGX / argenx SE ADS / Artisan Partners Limited Partnership - SC 13G/A Passive Investment

SC 13G/A 1 d443982dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 1)* Argenx SE (Name of Issuer) American Depositary Shares (Title of Class of Se

ARGNF / Argen X NV / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.8 ARGENX SE COMMON STOCK Cusip #N0610Q109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #N0610Q109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,437,779 Item 6: 0 Item 7: 5,532,356 Item 8: 0 Item 9: 5,532,356

ARGX / argenx SE ADS / BlackRock Inc. Passive Investment

SC 13G/A 1 nl0010832176020123.txt nl0010832176020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ARGENX SE - (Name of Issuer) Common Stock - (Title of Class of Securities) BWNH4H6 - (SEDOL Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa

EXTRAORDINARY GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES

Exhibit 99.3 EXTRAORDINARY GENERAL MEETING OF ARGENX SE EXPLANATORY NOTES The following item on the agenda of the extraordinary general meeting of argenx SE (the "Company") shall be discussed and/or put to a vote. The number in the list correspond to the number on the agenda. 2. Appointment of Steve Krognes as non-executive director to the board of directors of the Company (voting item) The Board

EXTRAORDINARY GENERAL MEETING OF ARGENX SE OF 27 FEBRUARY 2023

Exhibit 99.4 EXTRAORDINARY GENERAL MEETING OF ARGENX SE OF 27 FEBRUARY 2023 AGENDA 1. Opening 2. Appointment of Steve Krognes as non-executive director to the board of directors of the Company (voting item) 3. Any other business, announcements or questions 4. End of the extraordinary general meeting argenx SE Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands [email protected] – www.argenx.com

EXTRAORDINARY GENERAL MEETING OF ARGENX SE

Exhibit 99.2 EXTRAORDINARY GENERAL MEETING OF ARGENX SE CONVOCATION argenx SE (the "Company") hereby invites its shareholders and all other persons with meeting rights to attend its extraordinary general meeting of shareholders ("EGM") to be held at 12:00 PM CET on Monday afternoon, February 27, 2023 at Hilton Hotel Schiphol, Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. We would like

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-38097 ARGENX SE (Translation of registrant’s name into English) Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands (Address of principal executive of